Inventiva Uneventful preliminary 1H24 results, NATiV3 LPFV in 2H24
Inventiva reported uneventful preliminary 1H24 results. The next important milestone for the company is the last patient first visit (LPFV) in the phase 3 (NATiV3) trial of lanifibranor, for which the timeline guidance remains at 2H24 – this event would provide timeline certainty, pinning the timeline for the topline readout to early 2H26. Inventiva's cash runway was extended through September 2024 (previously early 3Q24) by the previously reported royalty certificates of approx. € 20m, which in our view provides breathing room for the company to seek the additional financing needed to reach topline readout in 2H26 (KBCSe >€ 150-200m). We reiterate our € 10 TP and BUY rating.Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.